Bausch Health Companies Inc. 2026年季度报告

BAUSCH HEALTH COMPANIESINC.FORM 10-Q INDEX PartI.Financial Information BAUSCH HEALTH COMPANIESINC.FORM 10-Q Introductory Note Except where the context otherwise requires, all references in this Quarterly Report on Form10-Q for the quarterly period endedMarch31, 2026 (this “Form10-Q”) tothe “Company”, “we”, “us”, “our” or similar words or phrases are to Bausch HealthCompaniesInc. and its subsidiaries, taken together. In this Form10-Q, references to“$” are to UnitedStates (“U.S.”) dollars, Trademarks This Form 10-Q contains trademarks, trade names and service marks that are the property of the Company, as well as, forinformational purposes, trademarks, trade names, and service marks that are the property of other organizations. Solely forconvenience, certain trademarks, trade names, and service marks referred to in this report appear without the ®, ™ and SM symbols, Forward-Looking Statements Caution regarding forward-looking information and statements and “Safe-Harbor” statements under the U.S.Private Securities This Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, asamended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and forward-lookinginformation within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). Forward-lookingstatements can generally be identified by the use of words such as “believe”, “anticipate”, “expect”, “intend”, “estimate”, “plan”,“continue”, “will”, “may”, “could”, “would”, “should”, “target”, “potential”, “opportunity”, “designed”, “create”, “predict”, These statements are based upon the current expectations and beliefs of management. Readers are cautioned that actual resultsmay vary from those in the forward-looking statements. Although we believe that the expectations reflected in such forward-lookingstatements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on suchstatements. Certain material factors or assumptions are applied in making such forward-looking statements, including, but not limitedto, factors and assumptions relating to: (i) our ability to execute our business strategy, business plans and operational efficiencyinitiatives; (ii) demand for, competitive positioning of and pricing for our current and anticipated products and our ability to achieveexpected revenues, margins and expense levels; (iii) the successful development, regulatory approval, manufacture and timing oflaunches and commercialization of pipeline and other products; (iv) the completion, timing, integration and expected benefits of acquisitions and other strategic transactions and the planned separation of our eye health business consisting of our Bausch + Lombglobal Vision Care, Surgical and Pharmaceuticals businesses on anticipated terms, timing and costs; (v) the scope, duration andfinancial and operational impact of product quality matters; (vi) the continued availability and performance of key third‑partydistribution, fulfillment and other arrangements and the stability of global supply chains; (vii) the continuation of patent protectionand regulatory exclusivity for key products; (viii) the expected impacts of the Inflation Reduction Act (“IRA”), and the selection by the We caution that, as it is not possible to predict or identify all relevant factors that may impact forward-looking statements, thefactors referred to in this Form 10-Q are not exhaustive and should not be considered a complete statement of all potential risks and Company, investors and others should carefully consider the aforementioned factors and other uncertainties and potential events.These forward-looking statements speak only as of the date made. We undertake no obligation to update or revise any of these Additional information about these factors and about the material factors or assumptions underlying such forward-lookingstatements may be found (i) in our Annual Report on Form 10-K for the year ended December31, 2025 under Item1A. “RiskFactors” and (ii) in the Company’s other filings with the U.S. Securities and Exchange Commission (the “SEC”) and the Canadian BAUSCH HEALTH COMPANIESINC.CONDENSED CONSOLIDATED BALANCE SHEETS(in millions, except share amounts)(Unaudited) BAUSCH HEALTH COMPANIESINC.NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DESCRIPTION OF BUSINESS Bausch Health Companies Inc. (the“Company” or “Bausch Health”) is a global, diversified specialty pharmaceutical and medicaldevice company that develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (“GI”), hepatology,neuroscience and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (“OTC”)products and aesthetic medical devices, and, through its approximately 87% ownership of Bausch + Lomb Corporation (“Bausch + SIGNIFICANT ACCOUNTING POLICIES